Stock

Buy BioNTech SE at the low PE of 2.31

BioNTech SE (NASDAQ:BNTX) is trading at $137.99. The 52-week range has been $121 to $464. The stock is trading near the bottom, and we think it is a buy.

BioNTech is A-rated for value, growth, and momentum. It is a good fit for any of the three investment styles. However, technical analysis would point to a holding decision mainly because of the bear market. The return ratios for BioNTech are some of the highest in the industry. ROE was recorded at 144%, while the ROA is 108%. The high return ratios are expected to continue supporting the stock.

Fundamental indicators suggest buying and holding the stock for the long term. BioNTech has a low forward PE of 2.31. This suggests that the stock is priced cheaply. Last year, the EPS was $49. This year’s EPS is expected at $61.

The return ratios for BioNTech are high and growing. The Achilles heel for the stock is the ability to grow sales. With COVID-19 vaccine sales declining, BioNTech will need to develop new products.

BioNTech consolidates between $137 and $179

Source – TradingView

BioNTech is consolidating between $137 and $179. At $137 the stock is at a support level. The MACD is mildly bullish. This analysis shows that BioNTech could pivot from the support and find the resistance level. At $137 the stock is definitely a buy.

Summary

BioNTech SE is a strong buy. The stock has high and growing ROE and EPS ratios. The PE of 2.31 indicates that the stock is cheaply valued by the market.

The post Buy BioNTech SE at the low PE of 2.31 appeared first on Invezz.

Disclaimer: MonopolyWinnersUpdates.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 MonopolyWinnersUpdates.com. All Rights Reserved.

To Top